Roche Launches 1,600-Patient Alzheimer’s Prevention Trial for Trontinemab
Updated
Updated · Bloomberg · Jul 15
Roche Launches 1,600-Patient Alzheimer’s Prevention Trial for Trontinemab
3 articles · Updated · Bloomberg · Jul 15
Summary
PrevenTRON will enroll 1,600 people who show biological signs of Alzheimer’s but have no cognitive impairment, making it a pivotal test of whether Roche’s antibody can delay symptoms before they start.
Trontinemab uses Roche’s Brainshuttle technology, which is designed to deliver higher and more consistent drug levels into the brain than standard antibodies.
Roche is pushing beyond Alzheimer’s treatment into prevention as it races Eli Lilly and Eisai to prove drugs can work earlier in the disease process.
With rivals offering at-home injections, can Roche's advanced IV drug win the Alzheimer's prevention race?
Should healthy people take risky drugs to prevent a disease they may never actually get?
Trontinemab in Alzheimer’s: Phase III Trials, Blood Test Screening, and the Race for Superior Efficacy and Safety by 2027
Overview
Roche has launched a major late-stage clinical program for trontinemab, including the pivotal Phase III TRONTIER 1, TRONTIER 2, and PrevenTRON trials for Alzheimer's disease. To streamline patient selection, Roche initiated the TRAVELLER pre-screening study, which uses the Elecsys pTau217 blood test—a less invasive and more affordable alternative to PET scans. This innovative approach enables broader community outreach, extends trial access to more diverse populations, and ensures participants better represent the wider Alzheimer's community. These efforts mark a significant step toward developing new, accessible treatments for Alzheimer's disease.